Andy Orth is the Chief Executive Officer of City Therapeutics. He is a seasoned biopharmaceutical leader with over 25 years of experience developing and commercializing novel medicines

Prior to joining City Therapeutics, Mr. Orth served as chief commercial officer of Krystal Biotech, where he drove company strategy and growth, and oversaw the global commercialization strategy and launch of VYJUVEK®, the first-ever topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa. Previously, Mr. Orth held multiple leadership roles at Alnylam Pharmaceuticals, including senior vice president, U.S. Region. In this role, he led Alnylam’s domestic business and launched the first-ever RNAi therapeutic, ONPATTRO®, for the treatment of the polyneuropathy of hATTR amyloidosis, followed by the launches of GIVLAARI® and OXLUMO®. Before Alnylam, Mr. Orth was on the Global Commercial Strategy and U.S. Business leadership teams at Biogen.

Earlier in his career, Mr. Orth held various finance roles with Genzyme and Amgen, as well as served as a research associate in the Osteoporosis and Arthritis Research Group at the University of California, San Francisco. Mr. Orth received his MBA from the Johnson Graduate School of Management at Cornell University and his undergraduate degree from the University of Wisconsin